Elinzanetant Efficacious, Well-Tolerated for Vasomotor Symptoms
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 27, 2024 -- For menopausal vasomotor symptoms (VMS), elinzanetant is efficacious and well-tolerated, according to a study published online Aug. 22 in the Journal of the American Medical Association.
JoAnn V. Pinkerton, M.D., from the University of Virginia Health in Charlottesville, and colleagues examined the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of moderate-to-severe menopausal VMS in two randomized, double-blind, phase 3 trials (OASIS 1 and 2), including postmenopausal participants aged 40 to 65 years. Eligible participants were randomly assigned to elinzanetant 120 mg for 26 weeks (199 and 200 in OASIS 1 and 2, respectively) or matching placebo for 12 weeks followed by elinzanetant 120 mg for 14 weeks (197 and 200 in OASIS 1 and 2, respectively).
The researchers found a significant reduction in VMS frequency with elinzanetant at week 4 (−3.3 and −3.0 in OASIS 1 and 2, respectively) and week 12 (−3.2 and −3.2 in OASIS 1 and 2, respectively). In addition, the severity of VMS was improved with elinzanetant at week 4 (−0.3 and −0.2 in OASIS 1 and 2, respectively) and week 12 (−0.4 and −0.3 in OASIS 1 and 2, respectively). Improvement in sleep disturbances and menopause-related quality of life was seen with elinzanetant at week 12, and the safety profile was favorable.
"Elinzanetant has the potential to provide a well-tolerated and efficacious nonhormonal treatment option to address the unmet health needs of many menopausal individuals with moderate-to-severe VMS," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Bayer, which manufactures elinzanetant and funded the OASIS 1 and 2 trials.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Survey Reveals Women May Be Experiencing Perimenopause in Their 40s
FRIDAY, April 25, 2025 -- Six in 10 women believe they will hit menopause in their 40s, according to survey results released April 8 by The Ohio State University Wexner Medical...
Common Photosensitizing Drugs Increase Skin Cancer Risk
TUESDAY, April 1, 2025 -- Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology...
Low Creatinine-to-Cystatin C Ratio Tied to Lower Muscle Volume in Midlife Women
MONDAY, March 31, 2025 -- Among middle-aged women, low creatinine-to-cystatin C ratio (CCR) at baseline is associated with lower fat-free muscle volumes and poorer gait speeds 6.6...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.